Nick Turner/bcrf.org
Jun 3, 2025, 14:56
Nick Turner on Targeting Breast Cancer Early with New Drug Camizestrant – ICR on SERENA-6 Trial at ASCO 2025
The Institute of Cancer Research shared a post on LinkedIn:
“BREAKING NEWS
A powerful new drug for advanced Breast Cancer can be used to treat emerging tumours, months before they have a chance to grow, helping to keep patients well for longer, according to new research presented today at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
Results of a global study, funded by AstraZeneca and co-led by researchers at The Institute of Cancer Research, London, The Royal Marsden NHS Foundation Trust and Institut Curie, Paris, showed advanced breast cancer patients who were given the new drug, called camizestrant, in combination with a CDK4/6 inhibitor cut the chances of their cancer getting worse by over half (56 per cent), allowing them to stay on first-line therapy for longer.
The SERENA-6 phase III trial is also the first global trial to demonstrate that using liquid biopsy blood tests to guide treatment at the right time – before clinical signs of progression appear – has a significant clinical benefit for this group of patients.
Co-principal investigator Professor Nick Turner, Professor of Molecular Oncology at The Institute of Cancer Research, London, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, shared his thoughts.
Read the full story here.”
Read more about SERENA-6 trial on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 4, 2025, 17:02
Jun 4, 2025, 16:33
Jun 4, 2025, 16:33
Jun 4, 2025, 15:56
Jun 4, 2025, 14:21